Vaxcyte to present results of VAX-24 infant Phase 2 study compared to Prevnar 20®.

From GlobeNewswire: 2025-03-30 17:00:00

Vaxcyte, Inc. announced a webcast and conference call on March 31, 2025, to present results from the VAX-24 infant Phase 2 study. The study compares the safety and efficacy of VAX-24, a 24-valent pneumococcal conjugate vaccine, to Prevnar 20® in healthy infants. The company is focused on developing high-fidelity vaccines to protect against bacterial diseases, with VAX-31 and VAX-24 in clinical trials. Vaxcyte is utilizing modern synthetic techniques to produce vaccines, including XpressCF™ cell-free protein synthesis platform. The company’s pipeline includes vaccines for Group A Strep infections, periodontal disease, and Shigella prevention.

For more information, visit www.vaxcyte.com.



Read more at GlobeNewswire: Vaxcyte to Host Webcast and Conference Call to Present